Liraglutide 3.0 mg reduces body weight and improves...

Obesity Research & Clinical Practice 2019 / 01 Vol. 13; Iss. 1

Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in adults with obesity or overweight, but without diabetes: The SCALE Obesity and Prediabetes randomised, double-blind, placebo-controlled 3-year trial

Markovic, Tania, Astrup, Arne, Greenway, Frank, Krempf, Michel, Le Roux, Carel W., Vettor, Roberto, Manning, Linda Shapiro, Lilleøre, Søren K., Fujioka, Ken
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Volume:
13
Journal:
Obesity Research & Clinical Practice
DOI:
10.1016/j.orcp.2016.10.079
Date:
January, 2019
File:
PDF, 47 KB
2019
Conversion to is in progress
Conversion to is failed